Jazz Pharmaceuticals Plc Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Mar'24

Net Sales

1,126.11

1,045.71

897.84

1,088.17

1,054.97

1,023.83

901.98

Other Operating Income

0.00

Total Operating income

1,126.11

1,045.71

897.84

1,088.17

1,054.97

1,023.83

901.98

Raw Material Cost

297.25

278.37

259.07

287.62

269.07

265.12

251.22

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

66.77

66.06

80.91

82.20

83.36

86.08

89.87

Selling and Distribution Expenses

469.15

358.40

514.01

369.29

325.77

338.52

351.71

Other Expenses

13.14

12.39

9.97

15.83

11.66

13.47

13.30

Total Expenditure (Excl Depreciation)

964.60

826.74

953.73

897.40

794.76

824.38

825.78

Operating Profit (PBDIT) excl Other Income

161.5

219

-55.9

190.79999999999998

260.2

199.4

76.2

Other Income

25.11

4.50

18.38

48.58

9.56

25.39

26.14

Operating Profit (PBDIT)

364.87

397.48

127.36

407.77

435.00

387.87

265.73

Interest

66.77

66.06

80.91

82.20

83.36

86.08

89.87

Exceptional Items

-110.82

-892.97

8.61

-23.93

14.40

-0.82

-14.09

Gross Profit (PBDT)

828.86

767.34

638.77

800.56

785.90

758.70

650.77

Depreciation

178.25

174.01

164.87

168.42

165.23

163.03

163.38

Profit Before Tax

9.04

-735.55

-109.81

133.22

200.81

137.93

-1.60

Tax

-242.42

-17.17

-17.81

-57.91

-14.53

-30.65

11.67

Provisions and contingencies

0.00

Profit After Tax

251.41

-718.47

-92.54

191.12

215.06

168.57

-14.62

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

251.41

-718.47

-92.54

191.12

215.06

168.57

-14.62

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

251.41

-718.47

-92.54

191.12

215.06

168.57

-14.62

Equity Capital

0.00

Face Value

0.0

Reserves

3,959.03

3,706.36

4,174.89

4,093.76

4,171.07

3,762.60

3,696.46

Earnings per share (EPS)

4.08

-11.74

-1.52

3.11

3.4

2.42

-0.23

Diluted Earnings per share

4.08

-11.74

-1.52

3.11

3.4

2.42

-0.23

Operating Profit Margin (Excl OI)

14.34%

20.94%

-6.23%

17.53%

24.67%

19.48%

8.45%

Gross Profit Margin

16.63%

-53.7%

6.13%

27.72%

34.7%

29.4%

17.94%

PAT Margin

22.33%

-68.71%

-10.31%

17.56%

20.38%

16.46%

-1.62%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - YoY

Net Sales

YoY Growth in quarter ended Sep 2025 is 6.74% vs 8.53% in Sep 2024

Consolidate Net Profit

YoY Growth in quarter ended Sep 2025 is 16.88% vs 46.53% in Sep 2024

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Sep 2025 is -20.12% vs 26.99% in Sep 2024

Interest

YoY Growth in quarter ended Sep 2025 is -19.90% vs -6.71% in Sep 2024

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Sep 2025 has fallen from Sep 2024

Compare Quarterly Results Of Jazz Pharmaceuticals Plc With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(USD)

Change(%)

Net Sales

1,126.11

1.57

1,124.54

71,626.75%

Other Operating Income

0.00

Total Operating income

1,126.11

1.57

1,124.54

71,626.75%

Raw Material Cost

297.25

1.03

296.22

28,759.22%

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

66.77

0.00

66.77

Selling and Distribution Expenses

469.15

142.20

326.95

229.92%

Other Expenses

13.14

16.46

-3.32

-20.17%

Total Expenditure (Excl Depreciation)

964.60

307.80

656.80

213.39%

Operating Profit (PBDIT) excl Other Income

161.51

-306.23

467.74

152.74%

Other Income

25.11

39.65

-14.54

-36.67%

Operating Profit (PBDIT)

364.87

-265.67

630.54

237.34%

Interest

66.77

0.00

66.77

Exceptional Items

-110.82

107.54

-218.36

-203.05%

Gross Profit (PBDT)

828.86

0.54

828.32

153,392.59%

Depreciation

178.25

0.92

177.33

19,275.00%

Profit Before Tax

9.04

-159.04

168.08

105.68%

Tax

-242.42

7.00

-249.42

-3,563.14%

Provisions and contingencies

0.00

Profit After Tax

251.41

-113.52

364.93

321.47%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

251.41

-113.52

364.93

321.47%

Share in Profit of Associates

0.00

Minority Interest

0.00

-52.52

52.52

100.00%

Other related items

0.00

Consolidated Net Profit

251.41

-166.04

417.45

251.42%

Equity Capital

0.00

Face Value

0.00

Reserves

3,959.03

4,362.33

-403.30

-9.25%

Earnings per share (EPS)

4.08

-0.17

4.25

2,500.00%

Diluted Earnings per share

4.08

-0.17

4.25

2,500.00%

Operating Profit Margin (Excl OI)

14.34%

-19,492.87%

0.00

19,507.21%

Gross Profit Margin

16.63%

-10,065.12%

0.00

10,081.75%

PAT Margin

22.33%

-7,225.91%

0.00

7,248.24%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 112.61 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is 7.69% vs 16.47% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 6.74% vs 8.53% in Sep 2024

Quarterly - Consolidate Net Profit

Consolidate Net Profit 25.14 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is 134.99% vs -676.76% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 16.88% vs 46.53% in Sep 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 33.98 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -13.54% vs 260.55% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -20.12% vs 26.99% in Sep 2024

Quarterly - Interest

Interest 6.68 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is 1.06% vs -18.29% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -19.90% vs -6.71% in Sep 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 14.34%

in Sep 2025

Figures in %

QoQ Growth in quarter ended Sep 2025 has fallen from Jun 2025

YoY Growth in quarter ended Sep 2025 has fallen from Sep 2024